Condoliase

Drug Profile

Condoliase

Alternative Names: C-ABC; ChABC; Chondroitinase ABC; SI-6603

Latest Information Update: 30 Aug 2016

Price : $50

At a glance

  • Originator Seikagaku Corporation
  • Class Chondroitin lyases
  • Mechanism of Action Chondroitin sulfate proteoglycan modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Intervertebral disc displacement

Most Recent Events

  • 29 Aug 2016 Condoliase licensed to Ferring Pharmaceuticals worldwide (excluding Japan)
  • 21 Jun 2016 Seikagaku announces intention to submit NDA to US FDA by 2019
  • 15 Jun 2016 Seikagaku signs a letter of intent with Ferring Pharmaceuticals for USA and overseas exclusive license agreement for condoliase for the treatment of Intervertebral disc displacement
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top